NCT06988943 Early Intervention Strategies for Lung Cancer
| NCT ID | NCT06988943 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University |
| Condition | Respiratory Tract Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 16,000 participants |
| Start Date | 2024-06-25 |
| Primary Completion | 2025-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 16,000 participants in total. It began in 2024-06-25 with a primary completion date of 2025-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Low-dose CT (LDCT）can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.
Eligibility Criteria
1.Community Health Service Centers (Cluster Level) 1. Inclusion Criteria The community health service center must be located within one of the 11 districts of Guangzhou. The center must manage a population of over 10,000 elderly individuals. The center should be equipped with at least one CT machine and have qualified medical personnel, such as radiologists, radiologic technicians, and nursing staff. 2. Exclusion Criteria Community health centers currently participating in other public health projects or studies that may affect screening results. Community health service centers where researchers cannot collect data or conduct follow-up. 2\. Screening Subjects (Individual Level) 1. Inclusion Criteria Aged 40-75 years. Residing in the community participating in the study for a long time. No known history of lung cancer and has not undergone lung cancer screening in the past three months. Able to understand and willing to sign the informed consent form, and able to participate in long-term follow-up. 2. Exclusion Criteria Individuals diagnosed with lung cancer. Individuals with severe other health issues that make them unsuitable for CT imaging. Individuals unable to understand the study protocol or who cannot provide informed consent due to cognitive impairments. Individuals participating in other clinical trials that may affect the results of this study. Individuals unable to undergo follow-up.
Contact & Investigator
Jianxing He, MD
PRINCIPAL INVESTIGATOR
Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College
Frequently Asked Questions
Who can join the NCT06988943 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 74 Years, studying Respiratory Tract Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06988943 currently recruiting?
Yes, NCT06988943 is actively recruiting participants. Contact the research team at drjianxing.he@gmail.com for enrollment information.
Where is the NCT06988943 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06988943 clinical trial?
NCT06988943 is sponsored by The First Affiliated Hospital of Guangzhou Medical University. The principal investigator is Jianxing He, MD at Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College. The trial plans to enroll 16,000 participants.